People with early-stage Alzheimer's disease who also have some form of dementia do not have appropriate access to the healthcare system for diagnosis and treatment. For instance, only about 50% of dementia patients receive a diagnosis, according to the 2016 World Alzheimer Report. The market for Alzheimer's drugs is predicted to grow due to the 10% underdiagnosis rate in low- and middle-income countries. Alzheimer’s Drugs Market were no set standards for disease diagnosis as of 2011. Currently, research is being done on biomarker tests that measure the amount of beta-amyloid in the brain, which can be seen in positron emission tomography imaging and used to diagnose and treat Alzheimer's disease. There is no effective treatment for Alzheimer's disease at the moment.
Read More @ https://cmiinfonest.blogspot.com/2022/07/global-alzheimers-drugs-market-trends.html
